- Home
- TNXP vs FRST Comparison
TNXP vs FRST Comparison
Compare TNXP & FRST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- FRST
- Stock Information
- Founded
- TNXP 2007
- FRST 2004
- Country
- TNXP United States
- FRST United States
- Employees
- TNXP N/A
- FRST N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- FRST Major Banks
- Sector
- TNXP Health Care
- FRST Finance
- Exchange
- TNXP Nasdaq
- FRST Nasdaq
- Market Cap
- TNXP 272.0M
- FRST 273.9M
- IPO Year
- TNXP N/A
- FRST 2006
- Fundamental
- Price
- TNXP $49.73
- FRST $11.72
- Analyst Decision
- TNXP Strong Buy
- FRST Buy
- Analyst Count
- TNXP 2
- FRST 1
- Target Price
- TNXP $585.00
- FRST $420.00
- AVG Volume (30 Days)
- TNXP 1.2M
- FRST 89.3K
- Earning Date
- TNXP 08-15-2025
- FRST 07-24-2025
- Dividend Yield
- TNXP N/A
- FRST 3.42%
- EPS Growth
- TNXP N/A
- FRST N/A
- EPS
- TNXP N/A
- FRST 0.36
- Revenue
- TNXP $10,041,000.00
- FRST $134,778,000.00
- Revenue This Year
- TNXP $22.87
- FRST $19.95
- Revenue Next Year
- TNXP $711.66
- FRST $12.14
- P/E Ratio
- TNXP N/A
- FRST $32.59
- Revenue Growth
- TNXP N/A
- FRST 26.02
- 52 Week Low
- TNXP $6.76
- FRST $7.59
- 52 Week High
- TNXP $130.00
- FRST $13.52
- Technical
- Relative Strength Index (RSI)
- TNXP 70.46
- FRST 63.35
- Support Level
- TNXP $41.64
- FRST $11.72
- Resistance Level
- TNXP $46.00
- FRST $12.11
- Average True Range (ATR)
- TNXP 3.70
- FRST 0.30
- MACD
- TNXP 0.38
- FRST -0.01
- Stochastic Oscillator
- TNXP 95.84
- FRST 64.55
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About FRST Primis Financial Corp.
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit. Its operating segments are Primis Mortgage, Primis Bank, and Other.